AuthorisedPhase III and phase IV (Integrated)Interventional

SCARP-DIAL (SGLT2i for CARdiovascular Protection in DIALysis)

The SCARP-DIAL study is looking at whether a medicine called dapagliflozin can help protect the heart in adults who receive regular dialysis. People on dialysis face a higher risk of heart disease, heart attacks, and strokes because kidney failure places extra stress on the heart and blood vessels. Dapagliflozin is already widely used to treat diabetes, heart failure, and chronic kidney disease. However, doctors want to know if it also offers strong heart protection for people whose kidneys have stopped working completely. In this trial, participants take the tablet alongside their standard treatment to see if it reduces serious heart events and hospital stays. The researchers will also examine whether the medicine improves daily quality of life and reduces the time it takes to recover after dialysis sessions. Taking part is completely voluntary and works alongside your normal NHS kidney care.

At a glance

Status

Authorised

Phase

Phase III and phase IV (Integrated)

Sponsor

Karolinska University Hospital

Enrolment target

1,000

Start

10 Sep 2026

Chronic dialysis, Cardiovascular disease

What is this study about?

Healthy kidneys remove extra fluid and waste products from your blood. When kidneys fail, dialysis takes over this essential role. However, living with kidney failure and having regular dialysis can put significant pressure on your heart and circulation. Because of this added strain, people on dialysis have an increased chance of developing heart complications, such as heart failure, heart attacks, or strokes.

Dapagliflozin is a tablet from a family of medicines called SGLT2 inhibitors. It is already well-known for helping people manage type 2 diabetes, kidney disease, and heart failure. Studies have shown it can keep the heart stronger and prevent hospital visits. Even so, there is still limited evidence on whether these benefits apply equally to people who are already receiving regular dialysis treatments.

The SCARP-DIAL clinical trial was set up to answer this important question. Researchers want to see if taking dapagliflozin can help dialysis patients stay healthier for longer. By comparing patients taking the medicine with those receiving standard care, the study hopes to discover whether dapagliflozin can lower the chance of major heart problems.

In addition to tracking heart events, the study is interested in how the treatment affects everyday life. Dialysis can leave people feeling exhausted, so the trial will monitor whether the tablet shortens recovery time after dialysis sessions and improves general energy and well-being.

Key takeaways

Tests whether the tablet dapagliflozin protects the heart in adults on dialysis.
Open to adults aged 18 and older who receive regular dialysis.
Measures the reduction in heart attacks, strokes, and emergency hospital stays.
Investigates whether the drug shortens recovery times after dialysis sessions.
Participation is voluntary and takes place alongside your routine NHS treatment.

Who may be eligible?

This study is designed for adults aged 18 and older who are receiving regular, long-term dialysis for kidney failure and who have, or are at high risk of, heart disease. Both men and women are welcome to take part.

To be considered, you must be established on chronic dialysis treatment, such as haemodialysis. Because the study focuses on heart health, doctors will look at your medical background to see if you meet the specific heart-related criteria for the trial.

You may not be eligible if you have certain other serious health issues, known allergies to dapagliflozin, or if you are taking medicines that cannot be mixed with the study drug. The trial team will carefully review your full medical history before you join to make sure it is safe for you.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

I am at least 18 years old.
I receive regular, long-term dialysis treatment (such as haemodialysis).
I have heart disease or have been told I am at risk of heart problems.
I am able to take a daily tablet as part of a clinical trial.
I am willing to answer questions about my health and symptoms during visits.

Answer every question to see your result.

What does participation involve?

If you decide to take part, you will be asked to take a daily study tablet alongside your normal care. Because you already attend regular dialysis sessions or kidney clinics, the study team will usually arrange trial check-ups to coincide with your routine hospital appointments to keep travel to a minimum.

During your visits, the research team will monitor your blood pressure, check your routine blood results, and ask you about any symptoms you may have noticed. You will also fill in simple questionnaires about your daily energy levels and how long you need to rest after each dialysis session. You will be followed up closely over several months or years so the team can monitor your heart health, and you will have access to a trial coordinator throughout.

Potential risks and benefits

Taking part may help protect your heart and could provide vital information to improve treatment for kidney patients across the UK, but personal benefits cannot be guaranteed. Like all medications, dapagliflozin can cause side effects. These may include low blood pressure, light-headedness, or mild fungal infections, though the medical team will watch you closely to manage any issues. Joining the study is entirely your choice. You have the right to withdraw at any point without giving a reason, and your regular dialysis and NHS care will not be affected.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

—
Unverified
Sweden

Common questions

What is dapagliflozin?

It is a tablet already prescribed in the UK to help manage diabetes, chronic kidney disease, and heart failure by easing strain on the heart and blood vessels.

Will taking part mean lots of extra hospital visits?

Study checks are usually scheduled during your routine dialysis sessions or regular clinic visits to minimise any extra travel for you.

Do I need to stop my regular kidney treatments?

No. You will continue having your scheduled dialysis and taking your regular prescribed medicines as advised by your kidney specialist.

What are the common side effects of dapagliflozin?

Potential side effects can include low blood pressure, mild dizziness, or minor infections such as thrush. Your study doctor will discuss all risks with you in detail.

Can I leave the study if I change my mind?

Yes. You can leave the trial at any time. Doing so will never alter the standard of medical care you receive from your kidney team.